Lifastuzumab

For research use only. Not for therapeutic Use.

  • CAT Number: I040848
  • CAS Number: 1615697-16-9
  • Purity: ≥95%
Inquiry Now

Lifastuzumab(CAT: I040848) is an investigational monoclonal antibody designed to target specific tumor-associated antigens for cancer therapy. It is being explored for its potential in oncology research, particularly in antibody-drug conjugate (ADC) development, where it delivers cytotoxic agents directly to cancer cells while minimizing off-target effects. Lifastuzumab’s mechanism of action enhances tumor cell destruction while preserving healthy tissues, making it a promising candidate for precision medicine in solid tumors and hematologic malignancies. With its high specificity and targeted therapeutic potential, Lifastuzumab contributes to advancements in cancer immunotherapy and personalized treatment strategies.


CAS Number 1615697-16-9
Purity ≥95%

Request a Quote